Octreotide

Amber-G

Brand Name(s):Sandostatin + LAR

Indication:Management of malignant bowel obstruction only when initiated by Palliative Care Service

Rationale:

Considered:Jan-12

Review Date:Apr-21

Comments:
Refer to Prescribing Guidance on Website
This guidance has been developed by the Palliative Care Team and relates to the management of malignant bowel obstruction.
…………………………
NICE NG 31
Care of dying adults in the last days of life
Full document available at:http://www.nice.org.uk/guidance/ng31/resources/care-of-dying-adults-in-the-last-days-of-life-1837387324357
Dec 2015